Patrick Trojer

Patrick Trojer, PhD, is the Chief Executive Officer and President of TRIANA Biomedicines, a biotechnology company in Greater Boston focused on molecular glue discovery for challenging disease targets, utilizing advanced structural insights and AI-driven drug discovery methods since November 2021. In addition to this role, Patrick serves on the Scientific Advisory Board for Fulcrum Therapeutics and as an advisor for RA Capital Management, L.P. and BiOrigin, all starting in 2022. Previously, Patrick held various leadership positions at Constellation Pharmaceuticals from 2010 to 2021, including Chief Scientific Officer and Vice President of Research. Patrick earned a Ph.D. in Biochemistry and Molecular Biology and an MS in Microbiology and Biochemistry, both from Universität Innsbruck.